

**Anti-LAG3 / CD223 Reference Antibody (favezelimab)
Recombinant Antibody
Catalog # APR10447****Specification****Anti-LAG3 / CD223 Reference Antibody (favezelimab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	P18627
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4SP
Calculated MW	145.4 KDa

Anti-LAG3 / CD223 Reference Antibody (favezelimab) - Additional Information**Target/Specificity**

LAG3 / CD223

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-LAG3 / CD223 Reference Antibody (favezelimab) - Protein Information**Name** LAG3 {ECO:0000303|PubMed:35761082, ECO:0000312|HGNC:HGNC:6476}**Function**

[Lymphocyte activation gene 3 protein]: Inhibitory receptor on antigen activated T-cells (PubMed:20421648, PubMed:35761082, PubMed:7805750, PubMed:8647185). Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells (PubMed:30580966, PubMed:32920841, PubMed:35761082, PubMed:39671469, PubMed:7589152).

target="_blank">7589152, PubMed:8647185, PubMed:9159144). Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (PubMed:40101708). Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation (PubMed:40101708, PubMed:40592325). May inhibit antigen- specific T-cell activation in synergy with PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:20421648, PubMed:7805750, PubMed:8647185). Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity).

Cellular Location

[Lymphocyte activation gene 3 protein]: Cell membrane; Single-pass type I membrane protein. Note=Clusters on the T-cell surface following ligand-binding

Tissue Location


Primarily expressed in activated T-cells and a subset of natural killer (NK) cells.


Anti-LAG3 / CD223 Reference Antibody (favezelimab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-LAG3 / CD223 Reference Antibody (favezelimab) - Images





Anti-LAG3 / CD223 Reference Antibody (favezelimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-LAG3 / CD223 Reference Antibody (favezelimab) is more than 95% ,determined by SEC-HPLC.